Part 2: Evidence Evaluation and Management of Conflicts of Interest

by Laurie J. Morrison, Lana M. Gent, Eddy Lang, Mark E. Nunnally, Melissa J. Parker, Clifton W. Callaway, Vinay M. Nadkarni, Antonio R. Fernandez, John E. Billi, Jonathan R. Egan, Russell E. Griffin, Michael Shuster, and Mary Fran Hazinski

Circulation
Volume 132(18 suppl 2):S368-S382
November 3, 2015

Applying Class of Recommendations and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care*.

CLASS (STRENGTH) OF RECOMMENDATION

CLASS I (STRONG) — Benefit >>> Risk

Suggested phrases for writing recommendations:
- Is recommended
- Is indicated/useful/effective/beneficial
- Should be performed/administered/other
- Comparative-Effectiveness Phrases†:
  - Treatment/strategy A is recommended/indicated in preference to treatment B
  - Treatment A should be chosen over treatment B

CLASS IIa (MODERATE) — Benefit >> Risk

Suggested phrases for writing recommendations:
- Is reasonable
- Can be useful/effective/beneficial
- Comparative-Effectiveness Phrases†:
  - Treatment/strategy A is probably recommended/indicated in preference to treatment B
  - It is reasonable to choose treatment A over treatment B

CLASS IIb (WEAK) — Benefit ≥ Risk

Suggested phrases for writing recommendations:
- May/might be reasonable
- May/might be considered
- Usefulness/effectiveness is unknown/unclear/uncertain or not well established

CLASS III: No Benefit (MODERATE) — Benefit = Risk
(Generally, LOE A or B use only)

Suggested phrases for writing recommendations:
- Is not recommended
- Is not indicated/useful/effective/beneficial
- Should not be performed/administered/other

CLASS III: Harm (STRONG) — Risk > Benefit

Suggested phrases for writing recommendations:
- Potentially harmful
- Causes harm
- Associated with excess morbidity/mortality
- Should not be performed/administered/other

LEVEL (QUALITY) OF EVIDENCE‡

LEVEL A
- High-quality evidence‡ from more than 1 RCTs
- Meta-analyses of high-quality RCTs
- One or more RCTs corroborated by high-quality registry studies

LEVEL B-R (Randomized)
- Moderate-quality evidence‡ from 1 or more RCTs
- Meta-analyses of moderate-quality RCTs

LEVEL B-NR (Nonrandomized)
- Moderate-quality evidence‡ from 1 or more well-designed, well-executed nonrandomized studies, observational studies, or registry studies
- Meta-analyses of such studies

LEVEL C-LD (Limited Data)
- Randomized or nonrandomized observational or registry studies with limitations of design or execution
- Meta-analyses of such studies
- Physiological or mechanistic studies in human subjects

LEVEL C-EO (Expert Opinion)

Consensus of expert opinion based on clinical experience

COR and LOE are determined independently (any COR may be paired with any LOE).

A recommendation with LOE C does not imply that the recommendation is weak. Many important clinical questions addressed in guidelines do not lend themselves to clinical trials. Although RCTs are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.

* The outcome or result of the intervention should be specified (an improved clinical outcome or increased diagnostic accuracy or incremental prognostic information).

† For comparative-effectiveness recommendations (COR I and IIa; LOE A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.

‡ The method of assessing quality is evolving, including the application of standardized, widely used, and preferably validated evidence grading tools; and for systematic reviews, the incorporation of an Evidence Review Committee.

COR indicates Class of Recommendation; EO, expert opinion; LD, limited data; LOE, Level of Evidence; NR, nonrandomized; R, randomized; and RCT, randomized controlled trial.

Laurie J. Morrison et al. Circulation. 2015;132:S368-S382

American Heart Association.

Structure of questions for evidence evaluation.



Laurie J. Morrison et al. Circulation. 2015;132:S368-S382

American Heart Association.

ILCOR 2015 Consensus on Science work flow for all systematic reviews.



Laurie J. Morrison et al. Circulation. 2015;132:S368-S382

American Heart Association.

ILCOR process for prioritizing PICO questions for systematic reviews.



Laurie J. Morrison et al. Circulation. 2015;132:S368-S382

American Heart Association.

Comparison of the number of systematic review questions (PICO questions) addressed or deferred/not reviewed in 2015 versus 2010 reported by Part in the ILCOR International Consensus on CPR and ECC Science With Treatment Recommendations (CoSTR) publication.



Laurie J. Morrison et al. Circulation. 2015;132:S368-S382

American Heart Association.

Class of Recommendation comparison between 2010 Guidelines and 2015 Guidelines Update.



Laurie J. Morrison et al. Circulation. 2015;132:S368-S382

Level of Evidence comparison between 2010 Guidelines and 2015 Guidelines Update.



Laurie J. Morrison et al. Circulation. 2015;132:S368-S382

American Heart Association.

Developing an AHA ECC recommendation that is informed by a GRADE strong recommendation in favor of a therapy or diagnostic or prognostic test.



Laurie J. Morrison et al. Circulation. 2015;132:S368-S382

Developing an AHA ECC recommendation that is informed by a GRADE weak recommendation in favor of a therapy or diagnostic or prognostic test.



Laurie J. Morrison et al. Circulation. 2015;132:S368-S382

American Heart Association.

Developing an AHA ECC recommendation that is informed by a GRADE strong or weak recommendation against a therapy or diagnostic or prognostic test.



Laurie J. Morrison et al. Circulation. 2015;132:S368-S382

American Heart Association.

The Utstein Formula of Survival, emphasizing the 3 components essential to improve survival.



Laurie J. Morrison et al. Circulation. 2015;132:S368-S382

American Heart Association.